28 October 2020 : Clinical Research
Need for Greater Attention to Joint Damage in Rhupus Patients: Results from an Ultrasound Study
Zhi-Xin Chen123BCE, Pei-Dan Yang12CDE, Min-Ying Liu12BCE, Ping-Fang Song4EF, Qiang Xu12AEFG*DOI: 10.12659/MSM.927104
Med Sci Monit 2020; 26:e927104
Table 3 Prednisone, DMARDs, and biologics used in rhupus patients and SLE with arthropathy patients.
| Medication use | Rhupus | SLE with arthropathy | P value |
|---|---|---|---|
| Prednisone, n (%) | 5/10 (50.00%) | 31/33 (93.90%) | 0.001* |
| Biological drugs used, n (%) | 2/10 (20.00%) | 0/33 (0.00%) | 0.009* |
| MTX, n (%) | 6/10 (60.00%) | 12/33 (36.40%) | 0.275 |
| HCQ, n (%) | 4/10 (40.00%) | 30/33 (90.10%) | 0.002* |
| LEF, n (%) | 2/10 (20.00%) | 2/33 (6.00%) | 0.226 |
| THH, n (%) | 6/10 (60.00%) | 8/33 (24.24%) | 0.055 |
| MMF, n (%) | 1/10 (10.00%) | 4/33 (12.12%) | >0.999 |
| CsA, n (%) | 0/10 (0.00%) | 2/33 (6.00%) | >0.999 |
| CTX, n (%) | 0/10 (0.00%) | 4/33 (12.12%) | 0.558 |
| MTX – methatrexate; HCQ – hydroxychloroquine; LEF – leflunomide; THH – tripterygium hypoglaucum hutch; MMF – mycophenolate mofetil; CsA – cyclosporine A;CTX – cyclophosphamide. * P | |||